| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.9 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |